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Abstract
Background/Aim. An ideal insulin regimen for children and
adolescents with type 1 diabetes mellitus (T1DM) should be
physiological, flexibile and predictable, protecting against hy-
poglycaemia. The aim of this study was to evaluate the influ-
ence of insulin analogues on glycaemic control and the occur-
ance of hypoglycaemic episodes in children and adolescents
with T1DM. Methods. The study group consisted of 151
children and adolescents (90 boys, 61 girls) treated with hu-
man insulins for at least 12 months before introducing insulin
analogues. All the patients were divided into two groups: the
group I consisted of 72 (47.7%) patients treated with three in-
jections of regular human insulin before meals and long-acting
analogue (RHI/LA), and the group II of 79 (52.3%) patients
treated with a combination of rapid-acting and long-acting
analogue (RA/LA). The levels of glycated hemoglobin
(HbA1c) and the number of hypoglycaemic episodes were as-
sessed at the beginning of therapy with insulin analogues, and
after 6 and 12 months. Results. The mean HbA1c was sig-
nificantly lower in the group I (RHI/LA) after 6 months
(9.15% vs 8.20%, p < 0.001) and after 12 months (9.15% vs
8.13%, p < 0.001) as well as in the group II (RA/LA) after 6
months (9.40% vs 8.24%, p < 0.001) and after 12 months of
insulin analogues treatment (9.40% vs 8.38%, p < 0.001). The
frequency of severe hypoglycaemia was significantly lower in
both groups after 6 months (in the group I from 61.1% to
4.2% and in the group II from 54.4% to 1.3%, p < 0.001), and
after 12 months (in the group I from 61.1% to 1.4% and in
the group II from 54.4% to 1.3%, p < 0.001). Conclusion.
Significantly better HbA1c values and lower risk of severe hy-
poglycaemia were established in children and adolescents with
T1DM treated with insulin analogues.
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Apstrakt
Uvod/Cilj. Idealan insulinski režim za decu i adoles-
cente sa dijabetesom melitusom tipa 1 (DMT1) trebalo bi
da bude fiziološki, fleksibilan i predvidljiv, kao i da štiti
od hipoglikemija. Cilj ove studije bio je procena uticaja
insulinskih analoga na stepen glikemijske kontrole i uÿe-
stalost hipoglikemijskih epizoda kod dece i adolescenata
sa DMT1. Metode. Ciljna grupa obuhvatila je 151 dete i
adolescenta (90 deÿaka, 61 devojÿica) koji su dobijali
humane insuline bar 12 meseci pre uvoĀenja insulinskih
analoga. Bolesnici su bili podeljeni u dve grupe: u prvoj
je bilo 72 (47,7%) dece leÿene sa tri injekcije regularnog
humanog insulina pre obroka i dugodelujuýim analogom
insulina (RHI/DA), a u drugoj grupi 79 (52,3%) dece le-
ÿene kombinacijom brzodelujuýeg i dugodelujuýeg ana-
loga insulina (BA/DA). Nivoi HbA1c i broj hipoglike-
mijskih epizoda registrovani su na poÿetku terapije insu-
linskim analozima, i posle 6 i 12 meseci. Rezultati. Sre-
dnja vrednost glikoziranog hemoglobina (HbA1c) bila je
znaÿajno niža u prvoj grupi (RHI/DA) posle 6 meseci
(9,15% vs 8,20%, p < 0,001) i posle 12 meseci (9,15% vs
8,13%, p < 0,001), kao i u drugoj grupi (BA/DA) posle 6
meseci (9,40% vs 8,24%, p < 0,001) i posle 12 meseci le-
ÿenja insulinskim analozima (9,40% vs 8,38%, p < 0,001).
Uÿestalost teških hipoglikemija bila je znaÿajno niža u
obe grupe posle 6 meseci (u prvoj grupi sa 61,1% na
4,2% i u drugoj sa 54,4% na 1,3%, p < 0,001) i posle 12
meseci (u prvoj grupi sa 61,1% na 1,4% i u drugoj sa
54,4% na 1,3%, p < 0,001). Zakljuÿak. Kod dece i ado-
lescenata sa DMT1 leÿenih insulinskim analozima utvr-
Āen je znaÿajno niži nivo HbA1c i manji rizik od teških
hipoglikemija.
Kljuÿne reÿi:
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Introduction
Ideally, insulin regimen for children and adolescents
with type 1 diabetes mellitus (T1DM) should be physiologi-
cal, flexibile, and predictable, in order to protect against hy-
poglycaemia 
1, 2. This goal is particularly difficult to achieve
in the paediatric patients, due to their susceptibility to hypo-
glycaemia, fluctuating insulin requirements caused by exer-
cise, illness, variable carbohydrate intake, psychosocial and
physiologic issues related to age, puberty, and weight
gain 
3, 4. The Diabetes Control and Complications Trial
(DCCT) and other landmark studies have shown that inten-
sive insulin therapy is associated with an increased risk of
hypoglycaemia 
3.
Compared to regular human insulin (RHI), the new
rapid-acting insulin analogues (RA, insulin aspart and lispro)
more closely resemble postprandial endogenous insulin se-
cretion by their faster onset and shorter duration of action
which reduces the risk of hypoglycaemia between meals and
during the first part of night as well as a need for snacks
between meals 
5, 6.
Long-acting insulin analogues (LA, insulin detemir and
glargine), have been developed with the aim of providing a
constant, flat and reproducible supply of basal insulin. Their
action starts within 1 to 2 hours and diminishes within 16 to
24 hours, with no pronounced peaks, which lowers the risk
of diurnal and nocturnal hypoglycaemia 
4, 7, 8.
The aim of this retrospective study was to evaluate the
influence of rapid-acting and long-acting insulin analogues
on metabolic control and frequency of hypoglycaemic events
in children and adolescents with T1DM.
Methods
The study group consisted of 151 children and adoles-
cents (90 boys, 61 girls) treated with human insulins (total
daily dose  1.5 U/kg) (Table 1). The primary inclusion cri-
terion was intensive treatment with human insulins for at
least 12 months. The second inclusion criterion was intro-
ducing insulin analogues due to unsatisfactory metabolic
control. All the patients were divided into two groups: the
group I consisted of 72 (47.7%) children treated with three
injections of regular human insulin before meals and long-
acting analogue (insulin detemir or glargine) at bedtime
(RHI/LA) and the group II of 79 (52.3%) children treated
with rapid-acting analogue (insulin aspart) as premeal insulin
and long-acting analogue at bedtime (RA/LA). The mean age
of patients at the beginning of treatment with insulin ana-
logues was 13.0 ± 2.2 years in the group I and 13.5 ± 2.4
years in the group II. A follow-up period for all the subjects
was 12 months, excluding 8 patients who were lost for fol-
low-up after 6 months because of transfer to adult endocri-
nologist.
In this observational, retrospective study data were
collected from medical records. The levels of glycated he-
moglobin (HbA1c) and the number of hypoglycaemic epi-
sodes were assessed at the beginning, and 6 and 12 months
after introducing insulin analogues. Hypoglycaemic episodes
were classified as minor (child could help itself) and major –
severe (requiring assistance to treat).
All data were analysed using the statistical package
SPSS (version 17.0). Data were reported as absolute numbers
and percentages, or as means and standard deviations (SDs).
Student’s t-test was used to assess the statistical significance
of differences between different insulin regimens and be-
tween the groups. Pearson’s Ȥ
2-test was used for comparison
of categorical variables. Changes in the means of frequency
and severity of hypoglycemic episodes were assessed using
Friedman and Wilcoxon signed ranks tests. p-values of less
than 0.05 were considered as statistically significant.
Results
The mean HbA1c was significantly lower in both
groups after 6 and 12 months. In the group I (RHI/LA)
HbA1c was lower after 6 months (9.15% vs 8.20%) and after
12 months (9.15% vs 8.13%) as well as in the group II
(RA/LA) after 6 months (9.40% vs 8.24%) and after 12
months of insulin analogues treatment (9.40% vs 8.38%) as
shown in Table 2. There were no significant statistical differ-
ences in HbA1c between the groups at the beginning and 6
and 12 months after introducing insulin analogues.
The frequency of hypoglycaemic episodes was signifi-
cantly lower in both groups 6 months after introducing insu-
lin analogues (100% to 87.5% in the group I, and 100% to
89.9% in the group II), and 12 months after introducing
analogues (100% to 83.3% in the group I, and 100% to
75.9% in the group II). The frequency of minor hypoglycae-
mic events was higher in both groups (Table 3) after 6
months (in the group I from 38.9% to 83.3%, and in the
group II from 45.6% to 88.6%) and after 12 months (in the
group I from 38.9% to 76.4%, and in the group II from
45.6% to 69.9%) while the frequency of severe hypoglycae-
mic events was significantly lower in both groups after 6
Table 1
Baseline characteristics of the 151 children and adolescents with type 1 diabetes mellitus
Patients characteristics Regular human insulin/Long-acting
analogue (RHI/LA)
Rapid-acting analogue/Long-acting
analogue (RA/LA)
All children, n (%) 72 (47.7) 79 (52.3)
Boys, n (%) 47 (65.3) 43 (54.4)
Girls, n (%) 25 (34.7) 36 (45.6)
Age of introducing analogues (years), ʉ ± SD 13.0 ± 2.2 13.5 ± 2.4
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months (in the first group decreased from 61.1% to 4.2%,
and in the group II from 54.4% to 1.3%) and after 12 months
(in the group I from 61.1% to 1.4%, and in the group II from
54.4% to 1.3%). There were no statistically significant dif-
ferences in frequency of hypoglycaemic episodes between
the groups at the beginning, and 6 and 12 months after intro-
ducing insulin analogues.
Discussion
It is widely accepted that the traditional insulins used in
basal-bolus therapy, regular human and neutral protamine
hagedorn (NPH) insulin, do not accurately reproduce the
physiological insulin profile. Insulin analogues have demon-
strated certain clinical improvements over regular human in-
sulin, and NPH insulin 
9–11. Data indicate that the combina-
tion of rapid-acting and long-acting analogues leads to over-
all improved glycaemic control in T1DM 
5, 11, 12.
The risk of hypoglycaemia is the most feared adverse
event among diabetes mellitus patients and medical staff in
relation to insulin treatment 
13, 14. Severe hypoglycaemia may
lead to long-term cognitive impairment in children below 6
years of age and similar effects may also apply for older
children 
15, 16. Treatment with insulin analogues is associated
with lower risk of hypoglycaemia, especially severe ones, in
children and adolescents with T1DM. It is likely that a com-
bination of rapid-acting and long-acting insulin analogues
produces a more physiological insulin secretion and thereby
reduces the risk of severe hypoglycaemia 
12.
In this retrospective study all the patients were already
on basal-bolus therapy recieving three injections of regular
human insulin before meals and NPH insulin at bedtime. In-
troducing long-acting insulin at bedtime or the combination
of mealtime rapid-acting and bedtime long-acting insulin
analogue resulted in improved glycaemic control with lower
risk of severe hypoglycaemia. The patients in both groups
experienced a decrease in HbA1c levels after introducing in-
sulin analogues with a small, but statistically significant dif-
ference of 0.96% in the group I and 1.16% in the group II
after 6 months, and 1.01% and 1.04% after 12 months. The
mean HbA1c levels were still significantly lower 12 months
after introducing insulin analogues in both groups. The fre-
quency of severe hypoglycaemia was significantly lower in
both groups 6 and 12 months after introducing insulin ana-
logues, but there were no statistically significant differences
between the groups. There were more patients with minor
hypoglycaemia, but those were ones that had severe hypo-
glycaemic events before introducing insulin analogues.
In the large-scale multicentre trial, Hermansen et al. 
5
showed that combination of insulin analogues, insulin de-
temir and insulin aspart, in addition to a significant im-
provement in HbA1c, provides a lower risk of hypoglycae-
mia than NPH and regular human insulin treatment. A meta-
analytsis of the Cochrane Metabolic and Endocrine Disor-
ders Group reviewed 42 randomized controlled trials that
compared the effect of intensified therapy regimens with
rapid-acting insulins to regular insulin in adults. The analy-
ses demonstrated a small, but statistically significant de-
crease in HbA1c using rapid-acting insulin analogues 
6, 17.
They mimic the normal mealtime insulin response more
closely than injection of regular human insulin and thereby
improve postprandial glycaemic control 
5, 10.
There are limited data regarding the use of rapid-acting
and long-acting insulin analogues in children and adolescents
Table 2
Glycated hemoglobin (HbA1c) before introducing insulin analogues and after 6 and 12 months
HbA1c (%), ʉ ± SD
Insulin therapy
before after 6 months after 12 months
Difference 95% CI p-value
8.20 ± 1.71 0.96 (0.6–1.2) < 0.001 RHI/LA 9.15 ± 2.25 8.13 ± 1.63 1.01 (0.6–1.3) < 0.001
8.24 ± 1.47 1.16 (0.9–1.4) < 0.001 RA/LA 9.40 ± 1.67 8.38 ± 1.66 1.04 (0.7–1.4) < 0.001
RHI/LA – 
 Combination of regular human insulin (RHI) and long-acting analogue (LA); 
 RA/LA – Combination of rapid-acting analogue (RA) and
long-acting analogue (LA).
Table 3
The frequency of hypoglycaemic events 6 and 12 months
after introducing insulin analogues
Hypoglycaemic events, n (%)
Insulin therapy
without minor severe p value
Before 0 28 (38.9) 44 (61.1)
After 6 months 9 (12.5) 60 (83.3) 3 (4.2) < 0.0001 RHI/LA
After 12 months 12 (16.7) 55 (76.4) 1 (1.4) < 0.0001
Before 0 36 (45.6) 43(54.4)
After 6 months 8 (10.1) 70 (88.6) 1 (1.3) < 0.0001 RA/LA
After 12 months 19 (24.1) 55 (69.9) 1 (1.3) < 0.0001
Before 0 64 (42.4) 87 (57.6)
After 6 months 17 (11.3) 130 (86.1) 4 (2.6) < 0.0001 Total
After 12 months 31 (20.5) 110 (72.8) 2 (1.3) < 0.0001
RHI/LA – 
 Combination of regular human insulin (RHI) and long-acting analogue (LA); 
 RA/LA – Combination of rapid-acting analogue (RA) and
long-acting analogue (LA).Strana 820 VOJNOSANITETSKI PREGLED Volumen 71, Broj 9
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compared to adults with T1DM. None showed a significant
decrease in HbA1c levels, and only one demonstrated lower
rates of hypoglycaemic episodes. Only few studies showed a
significant decrease in morning fasting blood glucose levels
and in the frequency of severe diurnal and nocturnal hypogly-
caemic episodes 
18. Chase et al. 
19 demonstrated a decrease of
HbA1c in addition to a significant decrease in severe hypogly-
caemia. In the first large-scale multicentre study Robertson et
al. 
2 showed the efficancy and safety of insulin detemir in chil-
dren and adolescents with T1DM. The lower risk of severe
hypoglycaemia with insulin detemir was achieved in children
without compromising glycaemic control. In all age groups the
quality of life seemed to improve with the insulin analogues,
which was attributed to less fear of hypoglycemia and more
flexibility in lifestyle and food intake 
4, 6, 17, 19.
Conclusion
This study demonstrated that insulin analogues used in
basal-bolus therapy, either only long-acting analogues with
premeal regular human insulin or the combination of rapid-
acting and long-acting analogues, provide significantly better
HbA1c values and lower risk of severe hypoglycaemic
events in children and adolescents with T1DM.
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